Physician profile
Robin A Sanger
NPI 1972546950
$1,219.86
in general payments reported to CMS, 2019-2025
14 companies · $84.73 in 2025
The $84.73 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $655 · 2022: $269 · 2023: $75.35 · 2024: $136 · 2025: $84.73.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $296.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $295.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $499.94 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $184.89 | 2021-2024 | |
| Abbvie INC. | $116.01 | 2021 | |
| Amarin Pharma, INC. | $111.14 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.56 | 2021 | |
| Lilly USA, LLC | $35.89 | 2022-2024 | Zepbound, Jardiance |
| Dexcom, INC. | $31.94 | 2023-2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $31.46 | 2022 | |
| Amgen INC. | $25.08 | 2022 | |
| Eisai INC. | $17.97 | 2021 | |
| Phathom Pharmaceuticals, INC. | $17.37 | 2024 | Voquezna |
| Sanofi-Aventis U.S. LLC | $16.55 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $15.25 | 2021 | |
| Horizon Therapeutics Plc | $14.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Sanger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.